Business
Recludix Pharma Announces Equity Financing to Advance Clinical Development of Novel SH2 Domain Inhibitors
Financing led by institutional investors, with participation from new investor Eli Lilly and CompanyInclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to dateSeparately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix’s discovery pipeline SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix
About this update from Eli Lilly And Company
[{"type":"image","alt":"Recludix Pharma, Inc.","displaySize":"","headline":null,"caption":"Recludix Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/026898f85cb6a19f92dd37096effd527"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LT.K7PPcvw4cLaZ9aUGNvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/026898f85cb6a19f92dd37096effd527","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Financing led by institutional investors, with participation from new investor Eli Lilly and Company","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Inclusive of this investment, a total of $123 million in equity financing received from institutional and strategic investors to date","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Separately, Recludix announces collaboration with Lilly to utilize Lilly TuneLab™, a pioneering artificial intelligence and machine learning platform, to accelerate the development of Recludix’s discovery pipeline","length":213,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":446,"olType":false},{"type":"text","content":"SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that it has completed an equity financing led by institutional investors -- including Access Biotechnology, Alexandria Venture Investments, NEA and Westlake BioPartners – alongside a strategic investment by Lilly.","length":417,"tagName":"p"},{"type":"text","content":"The company also announced that it has been selected by Lilly to access Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new medicines by providing biotech companies access to powerful drug discovery models that have been trained on Lilly’s proprietary research data. This collaboration will amplify the advanced computational capabilities of Recludix’s platform, thereby accelerating the progression of its novel SH2 domain discovery pipeline.","length":527,"tagName":"p"},{"type":"text","content":"“We are pleased to welcome Lilly and Alexandria...